دورية أكاديمية
أعرض في EDS

The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells.

التفاصيل البيبلوغرافية
العنوان: The effect of diabetes mellitus on differentiation of mesenchymal stem cells into insulin-producing cells.
المؤلفون: Badr OI; Pharmacology and Biochemistry Department, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt., Kamal MM; Pharmacology and Biochemistry Department, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt.; Drug Research and Development Group, Health Research Center of Excellence, The British University in Egypt, Cairo, Egypt.; Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt., El-Maraghy SA; Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Ghaiad HR; Biochemistry Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt. heba.mosalam@pharma.cu.edu.eg.
المصدر: Biological research [Biol Res] 2024 May 02; Vol. 57 (1), pp. 20. Date of Electronic Publication: 2024 May 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Biomed Central, Ltd Country of Publication: England NLM ID: 9308271 Publication Model: Electronic Cited Medium: Internet ISSN: 0717-6287 (Electronic) Linking ISSN: 07169760 NLM ISO Abbreviation: Biol Res Subsets: MEDLINE
أسماء مطبوعة: Publication: 2014- : London : Biomed Central, Ltd
Original Publication: Santiago : Society of Biology of Chile, [1992-
مواضيع طبية MeSH: Cell Differentiation*/physiology , Mesenchymal Stem Cells* , Rats, Sprague-Dawley* , Diabetes Mellitus, Experimental*/therapy , Insulin-Secreting Cells*/metabolism , Insulin*/metabolism, Animals ; Male ; Rats ; Mesenchymal Stem Cell Transplantation/methods ; Cells, Cultured ; Streptozocin ; Blood Glucose/analysis
مستخلص: Background: Diabetes mellitus (DM) is a global epidemic with increasing incidences. DM is a metabolic disease associated with chronic hyperglycemia. Aside from conventional treatments, there is no clinically approved cure for DM up till now. Differentiating mesenchymal stem cells (MSCs) into insulin-producing cells (IPCs) is a promising approach for curing DM. Our study was conducted to investigate the effect of DM on MSCs differentiation into IPCs in vivo and in vitro.
Methods: We isolated adipose-derived mesenchymal stem cells (Ad-MSCs) from the epididymal fat of normal and STZ-induced diabetic Sprague-Dawley male rats. Afterwards, the in vitro differentiation of normal-Ad-MSCs (N-Ad-MSCs) and diabetic-Ad-MSCs (DM-Ad-MSCs) into IPCs was compared morphologically then through determining the gene expression of β-cell markers including neurogenin-3 (Ngn-3), homeobox protein (Nkx6.1), musculoaponeurotic fibrosarcoma oncogene homolog A (MafA), and insulin-1 (Ins-1) and eventually, through performing glucose-stimulated insulin secretion test (GSIS). Finally, the therapeutic potential of N-Ad-MSCs and DM-Ad-MSCs transplantation was compared in vivo in STZ-induced diabetic animals.
Results: Our results showed no significant difference in the characteristics of N-Ad-MSCs and DM-Ad-MSCs. However, we demonstrated a significant difference in their abilities to differentiate into IPCs in vitro morphologically in addition to β-cell markers expression, and functional assessment via GSIS test. Furthermore, the abilities of both Ad-MSCs to control hyperglycemia in diabetic rats in vivo was assessed through measuring fasting blood glucose (FBGs), body weight (BW), histopathological examination of both pancreas and liver and immunoexpression of insulin in pancreata of study groups.
Conclusion: Our findings reveal the effectiveness of N-Ad-MSCs in differentiating into IPCs in vitro and controlling the hyperglycemia of STZ-induced diabetic rats in vivo compared to DM-Ad-MSCs.
(© 2024. The Author(s).)
References: Cell Tissue Res. 2018 Apr;372(1):91-98. (PMID: 29159483)
Biochem Biophys Res Commun. 2009 Jul 10;384(4):401-4. (PMID: 19410555)
World J Gastroenterol. 2004 Oct 15;10(20):3016-20. (PMID: 15378785)
Stem Cell Rev Rep. 2018 Jun;14(3):337-345. (PMID: 29611042)
Eur J Clin Nutr. 2017 Jul;71(7):904-912. (PMID: 28402325)
Cell Biosci. 2021 Nov 2;11(1):187. (PMID: 34727974)
J Biomed Mater Res A. 2014 Jul;102(7):2448-66. (PMID: 23894033)
Br J Haematol. 2007 Jun;137(6):491-502. (PMID: 17539772)
J Diabetes Res. 2015;2015:340838. (PMID: 26273667)
Birth Defects Res C Embryo Today. 2009 Sep;87(3):232-48. (PMID: 19750517)
Methods Mol Biol. 2011;702:37-46. (PMID: 21082393)
J Diabetes Metab Disord. 2020 Oct 17;19(2):1979-1993. (PMID: 33520872)
Bone. 2018 Dec;117:60-69. (PMID: 30208342)
Cytotechnology. 2014 Mar;66(2):299-307. (PMID: 23657630)
Front Endocrinol (Lausanne). 2021 Feb 26;12:631463. (PMID: 33716982)
Stem Cell Res Ther. 2020 Aug 3;11(1):336. (PMID: 32746936)
Nat Immunol. 2010 Feb;11(2):111-2. (PMID: 20084067)
Stem Cell Res Ther. 2017 Nov 2;8(1):240. (PMID: 29096722)
Diabetologia. 2008 Jul;51(7):1169-80. (PMID: 18491072)
J Clin Med. 2019 May 30;8(6):. (PMID: 31151180)
JAMA. 2017 Jun 27;317(24):2515-2523. (PMID: 28655017)
Stem Cells Int. 2022 Aug 22;2022:8637493. (PMID: 36045953)
Diabetes. 2015 Jul;64(7):2477-88. (PMID: 25765019)
Endocr Pathol. 2015 May;26(2):95-103. (PMID: 25762503)
Mol Ther. 2018 Aug 1;26(8):1921-1930. (PMID: 30005867)
Front Cell Dev Biol. 2020 Jan 29;8:16. (PMID: 32064260)
Front Cell Dev Biol. 2018 May 15;6:49. (PMID: 29868580)
J Clin Invest. 2008 Feb;118(2):789-800. (PMID: 18188455)
Stem Cells Int. 2022 Apr 13;2022:7556278. (PMID: 35463813)
J Clin Med. 2020 Jul 08;9(7):. (PMID: 32650555)
J Vis Exp. 2022 Aug 29;(186):. (PMID: 36094253)
J Mol Endocrinol. 2015 Apr;54(2):R103-17. (PMID: 25791577)
Biochem Biophys Res Commun. 2014 Jan 10;443(2):775-81. (PMID: 24148246)
Cytotherapy. 2006;8(4):315-7. (PMID: 16923606)
Mol Biol Cell. 2002 Dec;13(12):4279-95. (PMID: 12475952)
Cell Biochem Funct. 2010 Dec 2;28(8):637-43. (PMID: 21061411)
Cytometry A. 2018 Jan;93(1):19-31. (PMID: 29072818)
Biosci Rep. 2019 May 21;39(5):. (PMID: 31015367)
Regen Med. 2015;10(7):841-55. (PMID: 26541176)
J Mol Endocrinol. 2017 Oct;59(3):R109-R120. (PMID: 28739632)
Stem Cell Res Ther. 2019 Aug 28;10(1):274. (PMID: 31455405)
Oxid Med Cell Longev. 2016;2016:4710326. (PMID: 26682006)
Biochem Biophys Res Commun. 2002 Aug 23;296(3):589-95. (PMID: 12176022)
Cell Transplant. 2011;20(1):5-14. (PMID: 21396235)
J Clin Endocrinol Metab. 2023 Jul 14;108(8):1889-1897. (PMID: 36916961)
J Diabetes Investig. 2013 Nov 27;4(6):511-6. (PMID: 24843702)
Am J Stem Cells. 2018 Oct 01;7(4):82-93. (PMID: 30510843)
Diabetologia. 2014 Jan;57(1):246-56. (PMID: 24132782)
Diabetologia. 2020 Oct;63(10):2049-2056. (PMID: 32894315)
N Engl J Med. 2000 Jul 27;343(4):230-8. (PMID: 10911004)
Can J Surg. 2007 Apr;50(2):137-42. (PMID: 17550719)
Cell Transplant. 2012;21(6):1321-39. (PMID: 22195604)
Nat Rev Endocrinol. 2016 Oct;12(10):616-22. (PMID: 27388988)
J Cell Biochem. 2006 Aug 1;98(5):1076-84. (PMID: 16619257)
Hematol J. 2003;4(2):92-6. (PMID: 12750726)
Cell Rep. 2013 Sep 26;4(6):1262-75. (PMID: 24035389)
J Cell Biochem. 2022 May;123(5):906-920. (PMID: 35338509)
Stem Cell Res Ther. 2016 Aug 11;7(1):108. (PMID: 27515427)
Cell Death Dis. 2018 Jan 25;9(2):119. (PMID: 29371661)
Transplantation. 2010 Mar 27;89(6):686-93. (PMID: 20101199)
فهرسة مساهمة: Keywords: Adipose tissue; Diabetes mellitus; Differentiation; Insulin-producing cells; Mesenchymal stem cells
المشرفين على المادة: 0 (Insulin)
5W494URQ81 (Streptozocin)
0 (Blood Glucose)
تواريخ الأحداث: Date Created: 20240502 Date Completed: 20240503 Latest Revision: 20240521
رمز التحديث: 20240521
مُعرف محوري في PubMed: PMC11067316
DOI: 10.1186/s40659-024-00502-4
PMID: 38698488
قاعدة البيانات: MEDLINE
الوصف
تدمد:0717-6287
DOI:10.1186/s40659-024-00502-4